Since GSTM4 is a major GST specifically expressed in EWS/FLI-driven Ewing sarcoma cells and tumors, drugs preferentially activated by GSTM4 (i.e., GSTM4 pro-drugs) may be attractive therapeutics to target drug-resistant Ewing sarcoma. The gene discussed is GSTM4; the disease is Ewing sarcoma.